Similar articles

• Immunological aspects of motor neuron disease.

  Shy ME. Shy ME. Res Publ Assoc Res Nerv Ment Dis. 1990;68:241-56. Res Publ Assoc Res Nerv Ment Dis. 1990. PMID: 2183314 Review. No abstract available.
• A treatable multifocal motor neuropathy with antibodies to GM1 ganglioside.

  Pestronk A, Cornblath DR, Ilyas AA, Baba H, Quarles RH, Griffin JW, Alderson K, Adams RN. Pestronk A, et al. Ann Neurol. 1988 Jul;24(1):73-8. doi: 10.1002/ana.410240113. Ann Neurol. 1988. PMID: 2843079
• Immune-mediated models of motor neuron destruction in the guinea pig.

  Engelhardt JI, Appel SH, Jakab K, García J, Stefani E. Engelhardt JI, et al. Adv Neurol. 1991;56:369-79. Adv Neurol. 1991. PMID: 1853769 No abstract available.
• Immunoglobulins inhibit pathophysiological effects of anti-GQ1b-positive sera at motor nerve terminals through inhibition of antibody binding.

  Jacobs BC, O'Hanlon GM, Bullens RW, Veitch J, Plomp JJ, Willison HJ. Jacobs BC, et al. Brain. 2003 Oct;126(Pt 10):2220-34. doi: 10.1093/brain/awg235. Epub 2003 Jul 22. Brain. 2003. PMID: 12876146
• B cell-targeted therapy with rituximab and autoimmune neuromuscular disorders.

  Stübgen JP. Stübgen JP. J Neuroimmunol. 2008 Nov 15;204(1-2):1-12. doi: 10.1016/j.jneuroim.2008.07.019. J Neuroimmunol. 2008. PMID: 18783837 Review.